Flagship commits £100 million to London company-building lab
Flagship Pioneering has established Flagship Origination Lab, U.K., in London, committing an initial £100 million to its first dedicated company-creation unit outside the U.S. Operating within Flagship Labs, the team will conceive, test, fund and build AI-native platform companies focused on human and planetary health and other areas of science and technology.
The company expects to recruit and train approximately 50 scientist-entrepreneurs and operators in the U.K. Founder and CEO Noubar Afeyan said Flagship anticipates attracting an additional £500 million through partnerships. The lab will connect local company-building efforts with Flagship’s global infrastructure and business units, including Pioneering Intelligence and Pioneering Medicines.
The expansion follows Flagship’s London office opening and an agreement with the U.K. Government in 2023. Its existing British activities include launching transatlantic company Quotient Therapeutics, advancing clinical trials through Flagship-founded businesses such as Generate:Biomedicines, and developing academic, data and regulatory partnerships. Flagship cited the country’s scientific talent, clinical-trial infrastructure, genomics and health-data resources, and regulatory environment as reasons for choosing the U.K.